Try our beta test site
116 studies found for:    "idiopathic inflammatory myopathy"
Show Display Options
Download search resultsDownload the search results for:
"idiopathic inflammatory myopathy" (116 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Unknown  A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy
Condition: Idiopathic Inflammatory Myopathy
Intervention:
2 Recruiting MYOPROSP - a Prospective Cohort Study in Myositis
Conditions: Myositis;   Idiopathic Inflammatory Myopathy
Intervention:
3 Recruiting Belimumab in Myositis
Condition: Myositis
Interventions: Drug: Belimumab;   Drug: Placebo
4 Completed
Has Results
Arimoclomol in Sporadic Inclusion Body Myositis
Condition: Inclusion Body Myositis
Interventions: Drug: Arimoclomol;   Other: Placebo
5 Completed Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis
Interventions: Biological: BYM338;   Biological: Placebo
6 Completed Validation of Rehab Assessments in Myositis Patients
Condition: Myositis
Intervention: Device: Non intervention study
7 Completed Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis (sIBM)
Intervention: Drug: BYM338 (Bimagrumab)
8 Completed Lithium in Inclusion Body Myositis (IBM)
Condition: Inclusion Body Myositis
Intervention:
9 Completed Alemtuzumab to Treat Sporadic Inclusion Body Myositis
Condition: Myositis, Inclusion Body
Intervention: Drug: Alemtuzumab (Campath)
10 Not yet recruiting Study of Arimoclomol in Inclusion Body Myositis (IBM)
Condition: Inclusion Body Myositis
Interventions: Drug: Arimoclomol;   Other: Placebo
11 Completed Muscle Strength and Inflammatory Response in Patients With Inclusion Body Myositis
Condition: Inclusion Body Myositis
Intervention:
12 Active, not recruiting An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
Condition: Sporadic Inclusion Body Myositis
Interventions: Drug: Bimagrumab;   Drug: Placebo
13 Completed Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
Condition: Inclusion Body Myositis
Intervention: Drug: Etanercept
14 Active, not recruiting Natalizumab in Inclusion Body Myositis (IBM)
Condition: Inclusion Body Myositis (IBM)
Intervention: Drug: Natalizumab
15 Completed Blood-flow Restricted Exercise in Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis
Interventions: Other: Blood-flow restricted training;   Drug: Care as usual
16 Completed Treatment With TNF Blockade, Infliximab, in Patients With Myositis
Condition: Refractory Myositis
Intervention: Drug: Infliximab
17 Completed Immune Abnormalities in Sporadic Inclusion Body Myositis
Conditions: Sporadic;   Inclusion Body;   Myositis
Intervention:
18 Recruiting Adult and Juvenile Myositis
Conditions: Dermatomyositis;   Polymyositis;   Inclusion Body Myositis
Intervention:
19 Completed Anakinra in Myositis
Conditions: Polymyositis;   Dermatomyositis;   Inclusion Body Myositis
Intervention: Drug: Anakinra
20 Active, not recruiting Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis
Conditions: Becker Muscular Dystrophy;   Sporadic Inclusion Body Myositis
Intervention: Biological: rAAV1.CMV.huFollistatin344

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.